Skip Navigation

Advertise|Press|Contact|FAQ|About Us

Bookmark/Print/Share

Home » Clinical Trials » Amyloidosis

Clinical Trial Details

Overview

Research Study Summary

A clinical trial to evaluate treatments for patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

Research Study Title

A Phase 3, Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Purpose

This is a phase 3, randomized, controlled, open-label, multicenter study of the oral formulation of dexamethasone plus IXAZOMIB compared with treatment chosen by the investigator from a prespecified list of regimens available in clinical practice. Treatment options will include: dexamethasone alone, dexamethasone plus an alkylating agent (melphalan or cyclophosphamide), or dexamethasone plus an immunomodulatory drug (IMiD, thalidomide or lenalidomide) in patients with relapsed or refractory AL amyloidosis. Crossover to the investigational treatment arm is not permitted during participation in this study.

To Learn more
Phase

3

Gender

Both Male and Female

Age

18 and up

Overall Status

Recruiting

Lead Sponsor

Millennium Pharmaceuticals, Inc.

Duration

65 Months

Facility Type

N/A

Eligibility

Both Male and Female ages 18 Years and up

Inclusion Criteria:

  • Male or female patients 18 years or older

  • Biopsy-proven AL amyloidosis with relapsed or refractory disease despite 1 or 2 prior therapies. Patients may be proteasome inhibitor-exposed or naive, but cannot be refractory to proteasome inhibitor therapy

  • Disease requiring further treatment

  • Measurable disease as defined by serum differential free light chain concentration (dFLC)

  • Objective and measurable major organ involvement (ie, cardiac or renal) as defined by the standard International Society of Amyloidosis (ISA) criteria.

  • Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to 2

  • Meet the clinical laboratories criteria as specified in the protocol

  • Female patients who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception through 90 days after the last dose of study treatment or agree to practice true abstinence; must also adhere to the guidelines of any treatment specific pregnancy prevention program

  • Male patients who agree to practice effective barrier contraception through 90 days after the last dose of study treatment or agree to practice true abstinence AND must adhere to the guidelines of any treatment specific pregnancy prevention program

  • Voluntary written consent

Exclusion Criteria:

  • Amyloidosis due to mutations of the transthyretin gene or presence of other non-AL amyloidosis

  • Female patients who are lactating, breastfeeding or pregnant

  • Evidence of current uncontrolled cardiovascular conditions as specified in study protocol

  • Clinically overt multiple myeloma as specified in study protocol

  • Inability to swallow medication, inability or unwillingness to comply with the drug administration requirements, or gastrointestinal (GI) procedure that could interfere with the oral absorption or tolerance of treatment

  • Requirement for other concomitant chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered to be investigational or which would be considered as a treatment of AL amyloidosis. However, patients may be on chronic steroids (maximum dose 20 mg/day prednisone or equivalent if they are being given for disorders other than amyloidosis

  • Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Ongoing or active infection, known HIV positive, active hepatitis B or C infection

  • Psychiatric illness/social situations that would limit compliance with study requirements

  • Known allergy to any of the study medications, their analogues or excipients

  • Systemic treatment with strong inhibitors of CYP1A2, strong inhibitors of CYP3A, or strong CYP3A inducers, or use of Ginkgo biloba or St. John's wort within 14 days before the first dose of study treatment

  • Diagnosed or treated for another malignancy within 5 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection

Site Locations (57)

Country State City Zip Facility and Contact
United States Arkansas Little Rock Research Site
United States California Los Angeles Research Site
United States Illinois Chicago Research Site
United States Indiana Indianapolis Research Site
United States Massachusetts Boston Research Site
United States Michigan Detroit Research Site
United States Minnesota Rochester Research Site
United States Missouri Saint Louis Research Site
United States New York New York Research Site
United States Ohio Cleveland Research Site
United States Tennessee Nashville Research Site
United States Texas Dallas Research Site
United States Texas Houston Research Site
United States Wisconsin Milwaukee Research Site
Australia New South Wales Camperdown Research Site
Australia New South Wales Westmead Research Site
Australia Queensland Woolloongabba Research Site
Australia Western Australia Nedlands Research Site
Brazil Sao Paulo Research Site
Canada Alberta Calgary Research Site
Canada Alberta Edmonton Research Site
Canada British Columbia Vancouver Research Site
Canada Ontario Toronto Research Site
Czech Republic Moravskoslezsk kraj Ostrava Research Site
Denmark Aarhus Research Site
Denmark Copenhagen Research Site
France Loire-Atlantique Nantes Research Site
France Lille Research Site
France Limoges Research Site
France Paris Research Site
France Toulouse Cedex 9 Research Site
Germany Berlin Research Site
Germany Hamburg Research Site
Germany Heidelberg Research Site
Greece Achaa Patras Research Site
Greece Athens Research Site
Israel Haifa Research Site
Israel Jerusalem Research Site
Israel Kfar Saba Research Site
Israel Petah-Tiqva Research Site
Israel Ramat Gan Research Site
Italy Lombardia Pavia Research Site
Italy Bologna Research Site
Korea, Republic of Incheon Research Site
Korea, Republic of Seoul Research Site
Netherlands Noord-Holland Amsterdam Research Site
Netherlands AZ Maastricht Research Site
Netherlands Groningen Research Site
Netherlands Rotterdam Research Site
Netherlands Utrecht Research Site
Spain Castilla y Le0n Salamanca Research Site
Spain Cataluna Badalona Research Site
Spain Madrid Research Site
United Kingdom Oxfordshire Oxford Research Site
United Kingdom Birmingham Research Site
United Kingdom London Research Site
United Kingdom Manchester Research Site

Contact

For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center
1-877-674-3784
E-mail:

NCT ID: NCT01659658

Date Last Changed: December 18, 2014

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials. Some study summaries have been edited for clarity purposes to make them easier to understand. View more study details here.